Welcome to our dedicated page for DECOY THERAPEUTICS news (Ticker: DCOY), a resource for investors and traders seeking the latest updates and insights on DECOY THERAPEUTICS stock.
News about Decoy Therapeutics Inc. (DCOY) centers on its work as a preclinical-stage biotechnology company developing peptide-conjugate therapeutics using machine learning, artificial intelligence and high-speed peptide synthesis. Coverage commonly highlights progress on its IMP3ACT peptide-conjugate platform, early pipeline programs in respiratory viruses and GI cancers, and partnerships that support its technology and manufacturing capabilities.
One recurring news theme is Decoy’s focus on broad-acting antiviral candidates. The company has discussed a pan-coronavirus intranasal fusion inhibitor designed to help prevent and mitigate infections from multiple coronaviruses, particularly in immune-compromised and high-risk populations. It also reports work on a broad-acting antiviral intended to address flu, COVID-19 and respiratory syncytial virus (RSV), as well as a peptide drug conjugate for GI cancers.
Another important area of news involves Decoy’s Global Access Commitment Agreement with the Gates Foundation. Articles describe funded development of a flexible, globally accessible manufacturing platform for peptide-conjugate antivirals aimed at improving access in low- and middle-income countries. Updates may cover progress on establishing transferable manufacturing capabilities, collaborations with contract manufacturing organizations, and validation of the platform using Decoy’s pan-coronavirus inhibitor.
Investors and observers following DCOY news can expect updates on preclinical data, platform capabilities, global access initiatives and non-dilutive funding awards. This news page aggregates such announcements so readers can track how Decoy’s IMP3ACT platform, antiviral pipeline and peptide-conjugate oncology programs evolve over time.
Decoy Therapeutics (Nasdaq: DCOY) announced it regained compliance with Nasdaq Listing Rule 5550(a)(2) (the Minimum Bid Price Requirement) effective March 31, 2026. The company is reported to be in compliance with all other continued listing requirements, but will be subject to a Mandatory Panel Monitor for one year from that date.
If the Listing Qualifications Staff finds renewed noncompliance during the one-year monitoring period, Nasdaq may issue a delisting determination letter and the company could request a hearing with the Nasdaq Hearings Panel.
Decoy Therapeutics (Nasdaq: DCOY) announced a strategic partnership with Quantori, supported by funding from Google Cloud, to build a Google Cloud-native, AI-driven peptide design and molecular simulation platform.
The production-grade, GPU-accelerated platform will integrate folding models, molecular dynamics, and Decoy's IMP³ACT engine, targeting a ~25- to 100-fold increase in computational throughput to accelerate antiviral peptide discovery.
Decoy Therapeutics (NASDAQ: DCOY) will effect a 1-for-12 reverse stock split at 5:00 p.m. ET on March 6, 2026, with split-adjusted trading beginning March 9, 2026 under CUSIP 79400X602.
The split reduces outstanding shares from ~6.38 million to ~532,000 and is intended to help Decoy regain compliance with Nasdaq's $1.00 minimum closing bid requirement. Outstanding options, warrants, and plan reserves will be adjusted and fractional shares will be paid in cash.
Decoy Therapeutics (NASDAQ: DCOY) announced on Feb 11, 2026 that it joined the Webull Corporate Connect Service platform to provide an additional communication channel for shareholders and investors. The company said the portal will distribute corporate news, earnings reports, product updates, presentations and notifications to improve transparency and engagement.
Decoy Therapeutics (Nasdaq: DCOY) will present at the Corporate Connect Webinar Series hosted by Webull Financial on Tuesday, February 10, 2026 at 1:20 PM EST.
CEO Rick Pierce will give a brief corporate overview and highlight the company's new class of antiviral peptide conjugate therapeutics that target multiple viral pathogens.
Decoy Therapeutics (Nasdaq: DCOY) participated in a virtual investor "What This Means" segment on Feb. 4, 2026, detailing its Global Access Commitment Agreement (GACA) with the Gates Foundation.
The company described plans to develop a flexible, scalable manufacturing platform for peptide-conjugate antivirals using its IMP3ACT™ technology, validated by an intranasal pan-coronavirus fusion inhibitor funded under the same Gates Foundation grant.
Decoy Therapeutics (Nasdaq: DCOY) announced a Global Access Commitment Agreement with the Gates Foundation to fund development of a globally accessible, scalable peptide-conjugate manufacturing platform for antiviral therapeutics. The platform will be validated using Decoy's intranasal pan-coronavirus fusion inhibitor and built with U.S. and European contract manufacturers to enable rapid scale-up on standard peptide-synthesis machinery. Decoy expects to advance its lead pan-coronavirus antiviral to an IND filing within 12 months and progress programs for broad-acting flu/COVID-19/RSV antivirals and a peptide drug conjugate for GI cancers.